Hydroxylamine Derivatives as a New Paradigm in the Search of Antibacterial Agents by Miret Casals, Laia et al.
Hydroxylamine Derivatives as a New Paradigm in the Search of
Antibacterial Agents
Laia Miret-Casals,†,# Aida Baelo,‡,# Esther Juliań,§ Josep Astola,‡ Ariadna Lobo-Ruiz,†
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ABSTRACT: Serious infections caused by bacteria that are resistant to
commonly used antibiotics have become a major global healthcare problem in
the 21st century. Multidrug-resistant bacteria causing severe infections mainly
grow in complex bacterial communities known as biofilms, in which bacterial
resistance to antibacterial agents and to the host immune system is
strengthened. As drug resistance is becoming a threatening problem, it is
necessary to develop new antimicrobial agents with novel mechanisms of
action. Here, we designed and synthesized a small library of N-substituted
hydroxylamine (N-HA) compounds with antibacterial activity. These
compounds, acting as radical scavengers, inhibit the bacterial ribonucleotide
reductase (RNR) enzyme. RNR enzyme is essential for bacterial proliferation
during infection, as it provides the building blocks for DNA synthesis and
repair. We demonstrate the broad antimicrobial effect of several drug
candidates against a variety of Gram-positive and Gram-negative bacteria,
together with low toxicity toward eukaryotic cells. Furthermore, the most promising compounds can reduce the biomass of an
established biofilm on Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli. This study settles the starting point to
develop new N-hydroxylamine compounds as potential effective antibacterial agents to fight against drug-resistant pathogenic
bacteria.
■ INTRODUCTION
Ever since antibiotics were introduced worldwide, bacterial
pathogens have been developing resistance, which reduces
drastically or eliminates their effectiveness. The emergence of
drug-resistant bacteria is a growing challenge to anti-infective
therapy. Worldwide bacteria species that have acquired
multiple drug resistance and escaped the effects from our
current antimicrobial drugs include different important
bacterial pathogens.1 Several bacterial pathogens such as
methicillin- and vancomycin-resistant Staphylococcus aureus
(MRSA and VRSA) or multidrug resistant Pseudomonas
aeruginosa are resistant to almost all clinically available
antibacterial drugs.2 Moreover, recent estimates suggest that
bacterial biofilms account for over 80% of microbial infections
in the human body.3,4 Bacterial biofilms are dense aggregates
of cell−cell surface-attached microorganisms encased in a self-
synthesized hydrated extracellular polymeric substances
matrix.5 Bacterial pathogens living in biofilms are hard to
eradicate because of different strategies that involve restricted
penetration of antimicrobials, resistance to the immune system,
differential physiological activity with slow metabolism, the
presence of phenotypic variants and persisters, efflux systems,
and enhanced repair systems.6,7
The lack of new antibiotics in the drug development
pipeline, especially those with new modes of action and active
against bacteria, worsens the situation. In this context, the
search of new antimicrobials acting on new targets is a critical
challenge. Searching for new compounds or strategies to
decrease bacterial biofilm formation and avoid antibiotic
resistance is a critical stage essential for the treatment of
biofilm-associated diseases.8
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Ribonucleotide reductase (RNR) enzyme has shown to be
an antimicrobial drug target for the treatment of several
infections.9 RNR exclusively supplies the nucleotide precursors
for DNA synthesis and repair by catalyzing the reduction of
ribonucleotides (NTPs) to their corresponding deoxyribonu-
cleotides (dNTPs) via radical chemistry. Modulation of RNR
activity is a rate-limiting step in DNA synthesis. Therefore,
inactivation of RNR activity ceases DNA synthesis and,
consequently, inhibits cell proliferation. Thus, RNR is essential
for all bacteria causing both acute and biofilm infection, as they
need to multiply and replicate its genome within the host and,
therefore, need a constant supply of the four different dNTPs
for the synthesis of the new DNA.
Up to date, three different main RNR classes are described
(class I, II, and III), differing in their cofactor requirements and
quaternary structures.9−12 Class I RNR is additionally
subdivided into class Ia, class Ib, and class Ic, depending on
the metal type of the metallocofactor of the enzyme. Class I
RNRs are tetrameric (α2β2) enzymes, composed of two
homodimeric proteins: R1 (α2), which contains the catalytic
domain (active site) and the complex allosteric domain
(responsible for the regulation of the enzyme), and R2 (β2),
which carries a stable tyrosyl radical and an oxygen-linked
diiron center required for free-radical production. Once the
radical has been generated, an electron transfer takes place
between β2 and α2 subunits to catalyze the reduction of NTPs
to their corresponding dNTPs.
Although both bacteria and eukaryotic cells codify for RNR,
there are remarkable differences between them, as the
sequence similarity between them is quite low,13 and hence,
specific inhibitors can potentially be designed to differentially
target bacterial RNRs. In addition, eukaryotic cells only encode
for one RNR class (class Ia), whereas bacterial species can
encode simultaneously for different RNR classes, thus making
bacterial RNR system an attractive target for antibacterial
therapies.
Numerous and diverse RNR inhibitors have been described
during the last decades, including different inhibitor families
such as free-radical scavengers, iron chelators, and substrate
analogues, among others.14−18 Radical scavenger compounds
are well known to inhibit RNR by quenching an essential
tyrosyl free radical, located in the small class I subunit,19,20
which is required to generate the reduction power in the
catalytic subunit of the enzyme. Several radical scavenger
molecules, such as hydroxyurea (HU), didox, trimidox, and
hydroxyguanidine, have been shown to be useful for the
treatment of different cancer diseases.16 One of these
compounds, hydroxyurea, was used for general cancer
treatment and is commonly used nowadays for the treatment
of some specific ones.21,22 Although these compounds inhibit
bacterial replication inhibiting bacterial RNR, they cannot be
used to treat bacterial infections because of the high toxicity
toward eukaryotic cells. Recently, we have identified “NH−
OH” moiety as an important radical scavenger family by itself.
N-Methylhydroxylamine (M-HA) is a compound with a high
capacity to specifically inhibit the Bacillus anthracis RNR
without interfering the activity of eukaryotic RNR, thus being
nontoxic.19,20 We have also proven the antibacterial capacity of
this radical scavenger on Pseudomonas and Mycobacterium
infections.23 This discovery opens new horizons in the
Figure 1. Library of N-HAs. Chemical structures of the N-HA compounds, designed to target the bacterial RNR enzyme, are shown. The synthesis




ACS Omega 2018, 3, 17057−17069
17058
development, identification, and investigation of the use of N-
substituted hydroxylamine (N-HA) compounds as specific
antimicrobial RNR inhibitors.
■ RESULTS
Design and Synthesis of the N-HA Library. We
previously described the antibacterial activity of M-HA, a
radical scavenger compound that specifically targets bacterial
RNR without interfering the host enzyme.19,23 It is known that
low-molecular-weight compounds, such as M-HA, might have
effects on structurally unrelated proteins. For this reason, we
designed and synthesized a small library of N-HA compounds
with different structures to better cover the chemical space and
gain more selectivity (Figure 1) to directly target the bacterial
class I RNR enzyme (class Ia and class Ib), acting as an
antibacterial agent.
The N-HA library was generated to identify novel drugs with
high free-radical scavenging (FRS) activity against RNR
enzymes. As the FRS activity is based on the ability of the
molecule to donate a hydrogen ion to a free radical, FRS
activity of N-HAs will depend on the homolytic bond
dissociation enthalpies (BDEs) of the O−H bond of
hydroxylamines. It has been predicted by computational
methods that the resonance and the inductive effects are
important in the BDEs of the O−H bond of N-monosub-
stituted hydroxylamines. Thus, the design of N-HA with
electron-donating inductive effects and resonance effects
makes the corresponding N-oxyl species more electron-rich
and more stable radicals, leading to a BDE decrease24,25 and
thus resulting in a higher FRS activity. Otherwise, the presence
of electron-withdrawing groups or no resonance effects will
generate an opposite effect, destabilizing the produced radicals,
increasing BDE, and consequently, decreasing FRS activity.
The synthesis of N-HA products was accomplished by
reductive amination of aldehydes, as described before26 with
some variations, by a general one-pot synthesis that involves
the conversion of a carbonyl group to the hydroxylamine via
the corresponding N-hydroxyimine (Scheme 1).
Initially, N-alkyl hydroxylamine isomers of four carbon
atoms, including a secondary hydroxylamine and additional
analogues, increasing the alkyl chain length to increase the
electron-donating inductive effect to stabilize the generated
radical, were synthesized or purchased (1−6). Moreover, N-
cycloalkyl hydroxylamine derivatives were incorporated to the
library (7 and 8) to elucidate the importance of linear and
cyclic aliphatic structures in the stabilization of hydroxyl-
amine’s radicals. Replacement of the aliphatic moiety in N-
hydroxylamine compounds by an aromatic ring, such as benzyl
or homobenzyl group, was also explored to increase FRS
activity due to delocalization of the free radical throughout the
aromatic ring structure (9 and 10). To further study if radical
stabilization by resonance effects can be affected by inductive
effects, N-hydroxylamine compounds with electron-withdraw-
ing substituents in the aromatic ring, such as fluorine and
trifluoromethyl (11−15), were synthesized. In addition, the
library was further extended with a series of N-hydroxylamine
compounds with electron-donating substituents in the
aromatic ring, such as methyl and methoxy (16−19). Finally,
N-hydroxylamines containing a heteroaryl group or being part
of the heterocycle as secondary hydroxylamines were also
synthesized or purchased, respectively (20−22), to study the
ability of heteroaromatics in stabilizing N-oxyl species.
Identification of New N-Hydroxylamines (N-HAs)
with Antimicrobial Activity against Both Gram-Positive
and Gram-Negative Bacteria. In the antibacterial activity
screening of the newly synthesized N-HAs, compounds were
tested against four Gram-positive (B. anthracis, Staph. aureus,
Staphylococcus epidermidis, and Enterococcus faecalis) and two
Gram-negative (P. aeruginosa and Escherichia coli) clinically
relevant bacterial strains, and their minimum inhibitory
concentrations (MICs) were determined (Table 1). As a
reference, an importantly used antibiotic, ciprofloxacin (CIP),
was also tested. As shown in Table 1, we also included the M-
HA and HU antibacterial and cytotoxicity values to compare
them with the new data.
Some of the compounds (1−5, 7, 9, 13, 16, and 19−22)
showed no antibacterial activity in any bacteria tested (MIC50
> 1000 μg/mL) (data not shown). In general, Gram-positive
bacteria species (encoding class Ib RNR) were more sensitive
to 6, 8, 10, 11, 15, 17, and 18. In particular, compounds 11
and 17 with an MIC50 value of <15 μg/mL showed higher
activity compared to M-HA against B. anthracis. Compounds
11 and 15 showed also high antimicrobial activity against both
Staph. aureus and Staph. epidermidis with an MIC50 value of
<60 μg/mL compared to M-HA and HU. Compound 18 also
showed antibacterial activity against Staph. epidermidis with an
MIC50 value of <40 μg/mL. Compounds 14 and 17 showed
antimicrobial activity against E. faecalis with an MIC50 value of
<80 μg/mL.
Gram-negative bacterial species exhibited high resistance to
most of the compounds. Compound 8, showing values similar
to M-HA, was the most active, highly inhibiting the growth of
P. aeruginosa with an MIC50 value lower than 17 μg/mL and
that of E. coli with an MIC50 value lower than 60 μg/mL.
Compound 12 also resulted in high antimicrobial activity
against P. aeruginosa (MIC50 < 70 μg/mL), and compound 15
was also effective against E. coli (MIC50 < 60 μg/mL).
None of the N-hydroxylamine derivatives containing linear
alkyl groups with less than six carbon atoms were active against
any bacterial species tested, despite the fact that M-HA is
active with one carbon atom.
These results indicate that inductive effects generated by
linear alkyl groups with less than six carbon atoms are
insufficient to stabilize N-oxyl species, except for the case of M-
HA. Compound 6, a linear aliphatic N-hydroxylamine with six
carbon atoms, and compound 8, a cyclic aliphatic hydroxyl-
amine with seven atom carbons, exhibited antimicrobial
activity against Gram-positive and Gram-negative bacteria,
respectively. N-Homobenzylhydroxylamine (10) and some N-
benzylhydroxylamine analogues with substituents in the
aromatic ring (11, 12, 14, 15, 17, and 18) exhibited higher
antimicrobial activity compared to the aliphatic N-hydroxyl-
amines. These results might indicate that conjugate rings lead
to stable spin delocalized systems, providing stabilizing effects
for N-oxyl species radicals generated by reduction of the
tyrosyl radical of the RNR enzyme. This fact highlights the
importance of the resonance effects compared to the inductive
effects in the stabilization of radicals. Furthermore, the effect of
the delocalization of the free radical throughout the aromatic
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ring structure overlaps the inductive effect generated by
substituents in the aromatic ring. N-Hydroxylamine derivatives
with electron-withdrawing substituents and/or electron-donat-
ing substituents in the aromatic ring were active against several
bacterial species with no distinction. N-Hydroxylamines
containing a heteroaryl group or being part of the heterocycle
as secondary hydroxylamines showed no antibacterial activity
in any bacteria tested. However, N-benzylhydroxylamine
analogues (9, 13, 16, and 19) showed no antibacterial activity
and clearly demonstrate a challenge to capture a structure−
activity relationship. We believe that radical scavenger
molecules could interact in different places along the protein
electron chain transfer pathway from the β2 to the α2 subunits,
and this explains why radical scavengers without a common
scaffold are active.
Selected N-HA Compounds Exhibit Low Cytotoxicity
and Good Lipophilicity Indexes. To validate hydroxyl-
amine compounds to be used as drug candidates, eukaryotic
cytotoxicity of the compounds showing higher activity against
bacterial species (6, 8, 10−12, 14, 15, 17, and 18) was
determined in murine macrophages (see Experimental
Section) as described in our previous work.23 Compounds
with no antibacterial activity in the initial screening were
discarded.
The 50% cytotoxic inhibitory concentration (CC50) values
were determined from dose−response data obtained from the
toxicity assay of macrophages. Therapeutic indexes (selectivity
index, SI), defined as SI = CC50/MIC50, were calculated (see
Table 1) to measure drug safety (SI > 10). Compounds with
high CC50 and low MIC50 have higher therapeutic index and
are safer compared to compounds with low SI values.
Compounds 11, 15, 17, and 18 showed higher SI in Gram-
positive bacteria: in the case of B. anthracis, SI values of 21.3,
21.2, 45.2, and 45, respectively, and in Staph. aureus, SI values
of 5.3 and 11.4 for compounds 11 and 15, respectively.
Compounds 11, 15, and 18 showed SI values of 10.6, 11.4, and
10.4 in Staph. epidermidis, respectively. For Gram-negative
bacteria, the best SI values were achieved with compound 8 in
the case of P. aeruginosa (SI = 10.5) and compound 15 in the
case of E. coli (SI = 11.4). Although compound 12 was active
against P. aeruginosa, SI index was lower due to a lower CC50
value. Still, further studies were carried with this compound to
have more active N-HA compounds analyzed in the case of
Gram-negative bacteria. Clearly, some of the compounds
improve the SI values of the HU and M-HA compounds
previously analyzed, especially against Gram-positive bacteria.
To further test N-hydroxylamine compounds as drug
candidates, the lipophilicity of representative N-HA candidates
(8, 10, and 12−15) was measured by calculating the n-
octanol−water partition coefficients in their logarithmic form
(log P) (Figure 1). The majority of the N-hydroxylamine
analogues exhibited a moderate lipophilicity (log P between 0
and 3), indicating a good balance between solubility and
permeability, which is optimal for oral absorption and cell
membrane permeation through passive transport.
N-HA Compounds Inhibit Bacterial Growth through
their Radical Scavenging Activity in Bacterial RNR. To
confirm that novel N-hydroxylamines inhibit bacterial growth
by inhibiting radical formation in bacterial RNR, the FRS
activities of compounds showing antibacterial activity (6, 8,
10−12, 14, 15, 17, and 18) were evaluated through a radical
scavenging assay by trapping the DPPH· radical as previously
described27 (see Experimental Section). Ascorbic acid (AA),
HU, and M-HA were used as positive radical scavenger
controls (Table 2). After 8 h of incubation and using a DPPH·
concentration of 70 μM, compounds 8, 10, 11, 12, 14, 15, 17,
and 18 were able to scavenge the DPPH· radical with IC50
values of 9.3, 14.3, 6.4, 4.2, 23.1, 8.1, 4.8, and 6.5 μM,
respectively, showing similar scavenging activity as AA (IC50
=10.2 μM), HU (IC50 = 8.6 μM), and M-HA (IC50 = 20.3
μM). Similar values were obtained at 12 h incubation time.
However, compounds 2, 3, and 6, with linear aliphatic N-HA
with antibacterial activity, displayed a low FRS activity
compared to cyclic aliphatic hydroxylamine (8), N-homo-
benzylhydroxylamine (10), and N-benzylhydroxylamine ana-
logues (11, 12, 14, 15, 17, and 18) with IC50 values higher
than 140 μM. This study indicates that cyclic aliphatic rings
and aromatic rings make corresponding N-oxyl species more




compound Bant Saur Sepi Efae Paer Ecol CC50 (μg/mL)
6 55 (8.5) (-) (-) (-) (-) (-) 468 ± 7.64
8 60 (3) 60 (3) 60 (3) 120 (1.5) 17 (10.5) 60 (3) 178 ± 12.4
10 65 (4) 65 (4) 65 (4) (-) 125 (2) 125 (2) 259 ± 9.50
11 15 (21.3) 60 (5.3) 30 (10.6) 125 (2.6) (-) (-) 320 ± 5.03
12 (-) (-) 70 (1.9) (-) 70 (1.9) (-) 131 ± 21.9
14 (-) 150 (1.2) (-) 70 (2.4) 150 (1.2) (-) 168 ± 13.5
15 32 (21.2) 60 (11.4) 60 (11.4) (-) (-) 60 (11.4) 686 ± 45.4
17 8 (45.2) (-) 80 (4.5) 80 (4.5) (-) (-) 362 ± 20.4
18 40 (45) 175 (2.4) 40 (10.4) 175 (2.4) (-) (-) 415 ± 29.5
HU (-) 280 (0.1) 295 (0.1) 90 (0.33) 15 (2) 240 (0.1) 30 ± 3.4
M-HA 22 (14.5) 70 (4.6) 75 (4.2) 45 (7.1) 20 (16) 40 (8) 320 ± 20.4
CIP 0.5 (2600) 0.5 (2600) 0.5 (2600) 0.5 (2600) 0.25 (5100) 0.25 (5100) 1324 ± 49.3
aThe MIC50 values (μg/mL) measured after 8 h of N-HA compounds compared to HU, M-HA, and CIP (used as the positive control) are shown.
Data is representative of three independent experiments. bB. anthracis Sterne 7700 pXO1−/pXO2− (Bant), Staph. aureus ATCC 12600 (Saur),
Staph. epidermidis ATCC 1798 (Sepi), and E. faecalis ATCC 19433 (Efae). cP. aeruginosa ATCC 15692 (Paer) and E. coli O157:H7 (Ecol). (-), no
antibacterial activity (MIC50 > 250). Cytotoxicity values in murine macrophages measured after 24 h are indicated (CC50) as well as their SI (in
parenthesis next to the MIC50 value). Selectivity indexes of ≥5 are in bold. Compounds with MIC50 values over 1000 μg/mL in all the strains are
not shown (1, 2, 3, 4, 5, 7, 9, 13, 16, 19, 20, 21, and 22).
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electron-rich and more stable radicals, leading to a BDE
decrease and thus resulting in a higher FRS activity, as we
previously discussed. Also, our data supports the view that
these compounds exhibit a similar capacity to scavenge RNR
generated radical as other well-known RNR radical inhibitors
such as HU and M-HA do (see Table 2).
To evaluate the specific inhibitory effect of the N-HA
compounds in bacterial RNR, P. aeruginosa purine deoxy-
ribonucleotide levels were quantified at exponential phase in
the presence of N-HA compounds (8 and 12) and HU
(positive control) at 5 mM for 3 h and in the absence of or any
added compound (negative control) (Figure 2A). Relative
dNTP levels were quantified in the different extracts carrying
out the diphenylamine (DPA) assay.28,29 The results showed a
significant decrease of dNTP levels when P. aeruginosa was
treated with compounds 8 and 12 (7.45% and 67.50%
reduction, respectively) compared to negative control. HU,
used as the positive control, also showed a reduction of 65.45%
in dNTP levels.
The role of the radical scavenger HU in the inhibition of
RNR has been well studied. As many other enzymatic
inhibitors, when using HU, there is an induction of the
expression of the inhibited enzyme (RNR), as it has been
previously well described for us and many other authors.29,30
The induction of the expression of P. aeruginosa PAO1 class
Ia RNR (NrdA) was studied in the presence of the most active
N-HA radical scavengers against P. aeruginosa, using HU as a
positive control. A Western blot was performed using protein
extracts from PAO1 cultures in which HU, 8, or 12 was added
(at initial exponential phase and left for 3 h). As shown, both 8
and 12 were able to induce NrdA expression (1.6 and 3 times
more, respectively) compared to the negative control, which
was left without adding any compound. Compounds 8 and 12
had similar effects on NrdA expression to the ones HU shows
(nine times of induction), showing the direct effect of the
newly synthesized N-HA compounds on bacterial RNR
expression (Figure 2B).
N-HA Compounds Display Antibacterial Activity
through a Bacteriostatic Mode of Action. To better
understand how the most active N-hydroxylamines affect the
viability of bacterial cells in terms of physiological changes,
bacterial cells were imaged through fluorescence microscopy
using the Live/Dead viability assay (see Experimental Section),
which allows measuring bacterial viability in terms of
membrane integrity. SYTO 9 green fluorescent nucleic acid
dye is able to penetrate all membrane cells, labeling all bacteria,
whereas propidium iodide can only enter bacteria cells with
damaged membrane.
Staph. aureus, P. aeruginosa, E. coli, and B. anthracis growing
cultures at early exponential phase were incubated with
selected N-HA compounds showing greater antibacterial
action for 2 h then subsequently stained and imaged using
fluorescence microscopy (Figure 3). Images of bacteria also
treated with antibiotics novobiocin (NVB) and CIP were taken
to compare the effects with known antibiotics. N-HA
compounds did not affect membrane integrity of the cells, as
no differences were observed in the ratio of green cells (viable)
and red cells (nonviable) with or without any of the treatments
demonstrating a bacteriostatic property of these compounds.
The same effect was previously described for other radical
scavengers such as HU, hydroxylamine, and M-HA.23
N-HA Compounds Show Antibiofilm Activity against
Different Pathogens. Because most of the bacterial
infections in humans are in biofilm form,3,31 it is crucial to
study the antibacterial activity under the growth condition in
which bacteria are found naturally more resistant to the action
of antimicrobials.7,31 The most promising compounds showing
higher antibacterial activity, together with low cytotoxicity
(highest SI values), were evaluated on P. aeruginosa, Staph.
aureus, and E. coli static biofilms.
P. aeruginosa, Staph. aureus, and E. coli bacterial biofilms (72
h old) were established and treated with repeated admin-
Table 2. Radical Scavenging Capacity of the N-HAs
DPPH· scavenging activity (IC50 (μM))
a
compounds 8 h incubation time 12 h incubation time
2 >256 >256
3 >256 >256
6 171.4 ± 23.0 141.3 ± 17.4
8 9.3 ± 0.7 8.6 ± 0.5
10 14.3 ± 0.8 13.7 ± 0.9
11 6.4 ± 0.4 5.8 ± 0.3
12 4.2 ± 0.3 3.8 ± 0.3
14 23.1 ± 0.2 20.5 ± 0.3
15 8.1 ± 0.5 7.6 ± 0.5
17 4.8 ± 0.6 4.4 ± 0.8
18 6.5 ± 0.6 5.8 ± 0.6
AA 10.2 ± 1.8 10.1 ± 1.8
HU 8.6 ± 1.2 7.5 ± 0.9
M-HA 20.3 ± 2.0 18.1 ± 1.5
aRadical scavenging capacity was evaluated by measuring the
reduction of the free radical DPPH· spectrophotometrically after
incubating each compound with the DPPH during 8 and 12 h. AA,
HU, and M-HA were used as positive controls.
Figure 2. Inhibition of bacterial RNR by N-HA compounds. (A) In
vivo inhibition of bacterial RNR in P. aeruginosa was determined by
using DPA assay to estimate dNTP levels. Relative dNTP levels were
measured in protein extracts from mid-exponential cultures incubated
with or without 5 mM of the radical scavengers 8, 12, or HU (positive
control) for 3 h. Percentage of produced dNTPs is shown for each
sample using untreated culture as a reference. The results shown
represent the mean ± SD of two replicates of one representative
experiment. An unpaired t test, compared to the untreated sample,
was performed to evaluate significant differences (*, P < 0.05). (B).
Western blot analysis of class Ia RNR (NrdA) of bacteria at mid-
exponential phase cultured in the presence of 5 mM of 8, 12, or HU
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istration of selected compounds (one dose/24 h for three
consecutive days), and biofilm biomass was evaluated (Figure
4). CIP, a commonly used and known antibiotic, was used as a
positive control.
Figure 3. Bacterial viability after different compound treatments. Bacterial cultures were visualized under fluorescence microscopy after 2 h
exposition with the different N-HAs at 1× MIC concentration. Images were taken at 100×. Scale bars shown represent a real distance of 20 μm.
Live cells were green (SYTO 9 dye), and dead cells were red (propidium iodide dye). CIP and NVB (50 μg/mL) were used.
Figure 4. P. aeruginosa, Staph. aureus, and E. coli biofilms are inhibited by adding different concentrations of radical scavengers 8, 11, 12, and 15.
Bacteria were allowed to grow as biofilms in pegs (in the case of P. aeruginosa) or in wells (in the case of Staph. aureus and E. coli) for 72 h using 96
well microplates (see Experimental Section). Then, the medium was removed, and fresh medium with different concentrations of radical scavenger
compounds were changed every 24 h over 3 days (24 h, 48 h, and 72 h). The percentage of biofilm biomass was calculated by normalizing the data
for each of the nontreated biofilms for each day. The results shown are the means ± SD of four-six replicates from one representative of two
independent experiments. A Dunnett’s multiple comparison test was performed to detect significant differences. A Student’s t test was performed
(*, P < 0.05; vs nontreated biofilms). The viable counts at control experiments without a compound were 2.1 × 109 ± 2.8 × 108 colony-forming
units (cfu)/mL for PAO1, 9.8 × 109 ± 3.1 × 108 cfu/mL for Staph. aureus, and 3.3 × 1010 ± 1.8 × 109 cfu/mL for E. coli.
ACS Omega Article
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In the case of P. aeruginosa (Figure 4A), compound 8 clearly
reduced drastically the preestablished biofilm in more than
95% in P. aeruginosa at 48 h of treatment with an MIC
concentration of 16 μg/mL. Not so effective, compound 12
reduced above 55% of the established biofilm after 72 h of
treatment using the highest concentrations. CIP (0.5 μg/mL),
used as the positive control, reduced the preestablished biofilm
in more than 85%. Compound 8 showed higher activity
compared to CIP, demonstrating a good antibacterial activity
to eliminate P. aeruginosa biofilms.
Not so notorious but also important, compounds 11 and 15,
at MIC concentration, efficiently reduced Staph. aureus biofilm
at levels around 50% after 72 h of treatment (Figure 4B), with
similar levels to those reached when treating with CIP (around
60% reduction).
In the case of E. coli biofilms, compound 15 also successfully
removed static preestablished biofilm at more than 50% at 72 h
with the highest concentration (2× MIC concentration)
(Figure 4C), displaying low antibiofilm activity compared to
CIP. CIP-treated biofilm control (0.25 μg/mL) showed a
reduction of more than 90% formed biofilm.
To test some of the compounds under more natural
conditions that better resemble the in vivo infections, P.
aeruginosa continuous-flow biofilms were treated with two of
the most effective compounds (8 and 12) and CIP (positive
control) (Figure 5A) and observed by confocal laser scanning
microscopy (CLSM) demonstrating the capacity of these
compounds to decrease biofilm biomass and thickness. Note
that under this grown condition, the biofilm is extremely
resistant to all known antibiotics (with CIP, the formed biofilm
is only reduced around 50%).3
P. aeruginosa flow biofilms grew in a characteristic pattern
with a lawn of bacterial growth on the surface. These results
showed that compounds 8 and 12 at MIC concentration
clearly disrupted and inhibited P. aeruginosa flow biofilms.
Control experiments using CIP showed that a characterized
bacterial biofilm decreased, as previously described.32 When
analyzed using COMSTAT software, P. aeruginosa biofilms
showed significant structural differences in the presence of
both compounds (Figure 5B). Biomass and average thickness
decreased in biofilms grown in the presence of 8 (more than
50%) and 12 (more than 30%), indicating the ability of these
new radical scavengers to remove preexisting P. aeruginosa
growing in flow biofilms with similar results as compared to the
benchmarked antibiotic (CIP).
■ DISCUSSION
Because of the essential role of RNR in cellular replication, it
has been studied for a long time as an antibacterial target, and
different RNR inhibitors have been used as antiproliferative
therapies in cancer diseases.14,15,17 This is the case of HU, a
molecule with a hydroxylamine moiety that avoids RNR
activity by trapping a radical generated in the activator subunit
of the enzyme that is needed to initiate the catalysis.
As there is low similarity between some pathogenic bacteria
and the host RNR enzymes,19 it is possible to specifically target
bacterial enzyme without interfering eukaryotic cells and
avoiding host toxicity. In this sense, methyl hydroxylamine,
another radical scavenger compound with a hydroxylamine
moiety, as HU, was found to show antibacterial activity against
both P. aeruginosa and Mycobacterium bovis BCG without
reducing eukaryotic viability.19,20,23 This finding settled the
point for the design and development of new radical
scavengers with improved antibacterial activity that act against
antibiotic multiresistant bacteria.
In previous studies, the direct radical scavenging of the RNR
tyrosyl radical in the enzyme was demonstrated to take place
when using HU, hydroxylamine, and methylhydroxylamine.20,23
Here, we designed and synthesized a small-molecule library
of 16 N-HAs, incorporating six other molecules that were
acquired commercially (Figure 1). As the design of the new N-
HA chemical structures was based on a common N-
hydroxylamine moiety as the functional group involved in
the radical scavenging, we hypothesized the same mode of
action for our new N-HA compounds in RNR inhibition. As
expected, we could prove the radical scavenging activity of
different active N-HAs by measuring the reduction of the free
radical DPPH spectrophotometrically, showing the ability of
these compounds to quench free radicals as positive controls,
such as AA, HU, and M-HA, do (see Table 2). Moreover, we
demonstrated the effect of two of the N-HAs in reducing the
intracellular dNTP levels and inducing the protein expression
Figure 5. Effect of compounds 8 and 12 on a formed flow cell P. aeruginosa biofilm. Flow cell biofilm parameters after treatment with 8, 12, and
CIP (positive control). P. aeruginosa biofilm was cultured in a flow cell system for 96 h at room temperature and subjected to a continuous supply
of fresh medium at a flow rate of 3 mL/h. Different concentrations of compounds 8 and 12 and CIP were then used to treat biofilms for 24 h.
Afterward, biofilms were dyed with SYTO 9 and propidium iodide, rinsed, and imaged with CLSM. (A) ImageJ-analyzed CLSM micrographs of the
differently treated biofilms, showing the sum of the Z-projections and the corresponding orthogonal views of each biofilm (representative of 10
independent areas of two independent experiments). Green cells (dyed with SYTO 9) indicate viable cells, whereas red cells (dyed with propidium
iodide) indicate dead cells (damaged membrane). (B) Quantitative flow cell biofilm parameters (biomass and average thickness) of the biofilms,
quantified using Comstat2. A Student’s t test was performed (*, P < 0.05, vs nontreated biofilms).
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of P. aeruginosa class I RNR, as HU does29,33,34 (Figure 2),
making evident the clear role of these compounds in the
inhibition of bacterial RNR enzyme.
Antibacterial activity was assessed for all the library
compounds. Although some of the compounds exhibited no
antibacterial activity, nine of the new N-HAs were able to
inhibit the growth of different bacterial pathogens, including
Gram-negative and Gram-positive bacteria (see Table 1).
The library was composed of a wide diversity of structures,
including aliphatic and aromatic substituents, to better cover
the chemical space and gain selectivity toward the RNR
enzyme. As theoretically expected, some of the molecules with
cyclic aliphatic groups and aromatic groups showed better
activity against bacteria than the ones with linear aliphatic
groups, as it has been well described that radical scavenging
activities are related to aromatic structures as phenolic
compounds.17,35 To a great extent, N-benzylhydroxylamines
with substituents in the aromatic ring (10, 11, 12, 14, 15, 17,
and 18) were the ones with higher activity against Gram-
positive bacterial strains. This statement is also consistent with
the fact that lower radical scavenger activity is shown in N-HAs
with aliphatic substituents, such as 2, 3, and 6, which displayed
an IC50 at least 13 times higher than the other evaluated
compounds (Table 2). This is probably due to the fact that
electron delocalization in the aromatic ring favors the
stabilization of the free radical, thus providing higher FRS
activity. However, other N-benzylhydroxylamine analogues (9,
13, 16, and 19) showed no antibacterial activity, highlighting a
lack of structure−activity relationship. We assume that N-HA
molecules could quench the free radical in different places
along the protein electron chain transfer.
Overall, N-HAs resulted in higher antibacterial activity
against Gram-positive species rather than Gram-negative
species, excluding 8, which showed high activity against both
Gram-negative and Gram-positive bacteria. It is clear that some
of the new N-HA compounds (8, 11, 15, 17, and 18) result in
higher antimicrobial activity and SI compared to the HU and
M-HA. Gram-positive bacteria studied here (B. anthracis,
Staph. aureus, Staph. epidermidis, and E. faecalis) encode for a
specific class Ib RNR, whereas Gram-negative (P. aeruginosa
and E. coli) specifically encode for a class Ia RNR. Particularly,
E. coli also encodes for an additional class Ib RNR, although it
is not expressed under LB growing conditions.36 This
difference in RNR subclass is possibly the explanation of
such preference for Gram-positive RNR enzymes. We
previously described that M-HA showed better specific RNR
inhibition for class Ib RNR,19 thus demonstrating better
antimicrobial activity in bacteria expressing the class Ib RNR
subclass.23
How can such a diversity of molecule structures inhibit RNR
enzymes? More specifically, where does the radical scavenging
of such molecules take place? Class I RNR enzymes are made
up of two homodimeric subunits (α2β2): the large α2
homodimeric subunit called NrdA (class Ia) or NrdE (class
Ib) and the small β2 subunit called NrdB (class Ia) or NrdF
(class Ib). The large subunit (α2) is the catalytic subunit,
which harbors the substrate binding site and reduces the
different nucleotides to their corresponding dNTPs, whereas
the small β2 subunit contains an oxygen-linked diferric or
dimanganese metal center that generates a free tyrosyl radical.
Once the radical is generated, an electron transfer takes place
between β2 and α2 subunits from the specific radical site in the
small subunit to the substrate binding site in the large subunit
by a mechanism involving a long-range electron transfer
pathway.11,12
Docking experiments with other well-known radical
scavenger molecules, HU and p-allyloxyphenol, evidently
indicate that the molecule binding site is not well defined
and that in most of the cases, radical scavengers are located at
the protein surface.35 These experiments point out that the
large p-allyloxyphenol molecule cannot access the tyrosyl
radical site directly for structural reasons so that, for these
inhibitors, the radical scavenging action needs to be performed
during the long-range electron transfer pathway.35 Molecules
synthesized in this work have similar chemical structures and
molecular weights to p-allyloxyphenol, so we hypothesize the
same radical scavenger activity for the different N-HA
molecules described in this work as compared to the p-
allyloxyphenol. Probably, our N-HA molecules are not able to
diffuse to the place where the tyrosyl radical is formed (metal
center site at the small class I RNR subunit). Hence, the radical
scavenging activity could take place in different places along
the protein electron chain transfer. This fact could better
explain why different molecular scaffolds can inhibit RNR
enzymes with a similar scavenging activity.
Although some of the selected N-HAs displayed certain
toxicity to eukaryotic cells, others exhibited good therapeutic
index, which is a measure that takes into account both
cytotoxicity and antibacterial activity values. N-Hydroxylamine
compounds with SI > 5 are interesting and should be well
studied to be used as antibiotics, as bacteria were more affected
than eukaryotic cells. In addition, when analyzing the
lipophilicity levels of the most promising compounds, all of
them displayed moderate partition coefficients values, thus
indicating good solubility under physiological conditions.
One of the current antimicrobial therapy problems we are
currently facing is the use of antibiotics that are not effective to
eradicate bacteria growing in biofilms. Under this growing
condition, antibiotics cannot penetrate through the extrac-
ellular matrix produced by the different bacteria, or if they
penetrate, they can be inactivated by some components of the
matrix.7 This is the reason why bacterial infections growing
under biofilm conditions are extremely resistant to the current
chemotherapy, thus preventing the infection from being
eradicated. For this reason, evaluating antibacterial activity of
new molecules in biofilm-growing cells becomes essential if we
want to treat current infections.
When testing the ability of our new N-HA molecules to
eradicate bacterial biofilms, we found that some of the
compounds did reduce biofilm formation at levels similar to
those found for other known antibiotics, such as CIP. In the
case of P. aeruginosa, special attention needs to be done with
compound 8 that reduced above 90% of mature biofilm at 48 h
at the MIC concentration, which is similar to the levels of
inhibition with the benchmarked CIP (Figure 4). Not so
effective, but also important, were the results obtained with
Staph. aureus and E. coli biofilms, especially with a continuous 3
day treatment.
The antibiofilm activities of compound 8 were moreover
corroborated in a P. aeruginosa continuous-flow biofilm, which
was stained and observed by CLSM. The results certainly state
that compound 8 has the same effectivity as CIP to remove
well-established and mature P. aeruginosa biofilm (with similar
biomass and thickness values) (Figure 5).
P. aeruginosa is the responsible for some important chronic
pulmonary infections, such as those in cystic fibrosis (CF),
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bronchiectasis, or chronic obstructive pulmonary disease
(COPD). Our compounds could be effective for those
diseases, in which once the infection is established, eradication
of P. aeruginosa is nearly impossible due to a biofilm form of
growth. As the existing therapies always fail to eradicate
bacterial biofilms, the results outlined herein show that our
compounds could be highly potent and effective drugs to
eradicate biofilm infections and open an interesting new era of
research in this field. In addition, antibiofilm candidates are
ultimately explored to be used not only in clinical settings but
also in eliminating contaminating biofilm growth in food and
veterinary industry, processes that involve pure water systems.
■ CONCLUSIONS
In summary, we designed and synthesized a library of N-HA
compounds, acting as radical scavengers, to directly target the
bacterial class I RNR enzyme and inhibit bacterial prolifer-
ation. Compounds with different structures were designed to
better cover the chemical space and gain more selectivity. We
have demonstrated the broad antimicrobial effect of several
drug candidates against a variety of Gram-positive and Gram-
negative pathogenic bacteria, together with low toxicity toward
eukaryotic cells. In addition, some of the compounds had the
ability to eradicate bacterial biofilms at the same level of known
antibiotics. This work settles the starting point to develop new
radical scavenger compounds as potential antibacterial agents
to fight against drug-resistant pathogenic bacteria.
■ EXPERIMENTAL SECTION
All reagents used for chemical synthesis were purchased from
commercially available sources and used without further
purification. Nuclear magnetic resonance (NMR) solvents
were obtained from Sigma-Aldrich. 1H, 13C, and 19F NMR
spectra were recorded on a Varian MERCURY 400
spectrometer (400 MHz for 1H NMR, 101 MHz for 13C
NMR, and 376 MHz for 19F NMR). Chemical shifts (δ) are
expressed in parts per million (ppm) downfield from
tetramethylsilane, and deuterated solvent signal was used as
reference. Coupling constants (J) are expressed in hertz (Hz).
Abbreviations used are s = singlet, bs = broad singlet, d =
doublet, dd = doublets of doublets, t = triplet, td = triplets of
doublets, q = quartet, and m = multiplet. Mass spectra were
obtained at the “Centres Cientifícs i Tecnolog̀ics de la
Universitat de Barcelona” (CCiTUB). Compounds tested in
the different biological assays were previously diluted to a stock
concentration of 0.5 to 1 M in H2O to perform the
experiments.
General Procedure for the Synthesis and Character-
ization of N-HAs. N-HAs were synthesized by reductive
amination of aldehydes, as described before26 with some
variations. To a mixture of R-aldehyde (1 equiv) in a solution
of 5.0 M LiClO4/Et2O (LPDE) (10 mL), O-(trimethylsilyl)-
hydroxylamine (1.5 equiv) was added at room temperature.
The mixture was stirred for 10 min, and trimethylsilyl chloride
(1.5 equiv) was added. After stirring the mixture for 8 h,
borane/triethylamine complex (1.5 equiv) was added, and the
reaction mixture was allowed to stir at room temperature
overnight. The reaction was quenched with a saturated
aqueous NaHCO3 solution to obtain the mono N-alkylhy-
droxylamine. The mixture was filtrated, and then the product
was extracted with DCM. The organic extracts were combined,
dried with MgSO4, and concentrated. Finally, the crude
product was flash-chromatographed (SiO2) using a hexane−
EtOAc gradient from 1:0 to 0:1.
All final compounds were confirmed by 1H NMR, 13C
NMR, 19F NMR (see Supporting Information for product
characterization), and HR-ESMS. In all cases, the purity of the
final product was above 95% after flash chromatography
(SiO2).
Compounds 1, 2, 6, 8, 10, 11, 15, 16, 18, and 20 were
synthesized as previously described, and their characterization
agrees with the literature.
N-Hydroxy-3-methylbutan-1-amine (5). Isovaleraldehyde
(1 g, 11.6 mmol) was dissolved in a solution of 5.0 M LPDE.
Then, O-(trimethylsilyl)hydroxylamine (17.4 mmol), trime-
thylsilyl chloride (17.4 mmol), and borane/TEA complex
(17.4 mmol) were added as described in the general
procedure. Following purification via flash column chromatog-
raphy, the product was obtained in a 56.4% yield. 1H NMR
shows a conformer. 1H NMR (400 MHz, CDCl3) δ ppm 6.48
(bs, 2H, NHOH), 2.93−2.89 (m, 2H, CH2), 1.65−1.52 (m,
1H, CH), 1.41−1.35 (m, 2H, CH2), 0.87 (d, J = 6.6 Hz, 6H,
CH3). Isolated signals of the conformer: 3.38 (t, J = 7.4 Hz,
2H, CH2), 1.86−1.75 (m, 1H, CH), 0.90 (d, J = 6.9 Hz, 6H,
CH3).
13C NMR (101 MHz, (CD3)2CO) δ ppm 58.9 (t), 37.7
(t), 27.5 (d), 23.6 (2q). HRMS (ESI) m/z calcd for C5H14NO:
104.1075 [M + H]+; found, 104.1070.
N-(4-Fluoro-2-methylbenzyl)hydroxylamine (12). 4-Fluo-
ro-2-methylbenzaldehyde (1 g, 7.2 mmol) was dissolved in a
solution of 5.0 M LPDE. Then, O-(trimethylsilyl)-
hydroxylamine (10.9 mmol), trimethylsilyl chloride (10.9
mmol), and borane/TEA complex (10.9 mmol) were added
as described in the general procedure. Following purification
via flash column chromatography, the product was obtained in
a 55.2% yield. 1H NMR (400 MHz, D2O) δ ppm 7.46 (dd, J =
8.44, 5.96 Hz, 1H, ArH), 7.12 (dd, J = 10.05, 2.42 Hz, 1H,
ArH), 7.06 (td, J = 8.54, 2.35 Hz, 1H, ArH), 4.51 (s, 2H,
CH2), 2.43 (s, 3H, CH3).
13C NMR (101 MHz, D2O) δ ppm
163.1 (d), 141.7 (s), 133.51 (d), 122.8 (s), 117.4 (d), 113.2
(d), 51.5(t), 18.5 (q). 19F NMR (376 MHz, D2O) δ ppm
−112.40−(−112.49) (m, 1F, CF). HRMS (ESI) m/z calcd for
C8H11FNO: 156.0819 [M + H]
+; found, 156.0819.
N-(4-Fluoro-2-(trifluoromethyl)benzyl))hydroxylamine
(13). 4-Fluoro-2-(trifluoromethyl)benzaldehyde (1 g, 5.2
mmol) was dissolved in a solution of 5.0 M LPDE. Then, O-
(trimethylsilyl)hydroxylamine (7.8 mmol), trimethylsilyl chlor-
ide (7.8 mmol), and borane/TEA complex (7.8 mmol) were
added as described in the general procedure. Following
purification via flash column chromatography, the product
was obtained in a 46.7% yield. 1H NMR (400 MHz, CD3OD)
δ ppm 7.89 (dd, J = 8.46, 5.26 Hz, 1H, ArH), 7.63 (dd, J =
8.95, 2.72 Hz, 1H, ArH), 7.55 (td, J = 8.46, 2.72 Hz, 1H, ArH),
4.93 (bs, 2H, NHOH), 4.61 (s, 2H, CH2).
13C NMR (101
MHz, CD3OD) δ ppm 164.3 (d), 137.2 (d), 133.2 (s), 124.7
(s), 124.5 (q), 120.9 (d), 115.5 (d), 52.1 (t). 19F NMR (376
MHz, CD3OD) δ ppm −60.22 (s, 3F, CF3), −110.52−
(−110.57) (m, 1F, CF). HRMS (ESI) m/z calcd for
C8H8F4NO: 210.0537 [M + H]
+; found, 210.0546.
N-(3,5-Difluorobenzyl)hydroxylamine (14). 3,5-Difluoro-
benzaldehyde (1 g, 7 mmol) was dissolved in a solution of
5.0 M LPDE. Then, O-(trimethylsilyl)hydroxylamine (10.6
mmol), trimethylsilyl chloride (10.6 mmol), and borane/TEA
complex (10.6 mmol) were added as described in the general
procedure. Following purification via flash column chromatog-
raphy, the product was obtained in a 49.8% yield. 1H NMR
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(400 MHz, D2O) δ ppm 7.25−7.03 (m, 3H, ArH), 4.47 (s,
2H, CH2).
13C NMR (101 MHz, D2O) δ ppm 162.8 (d),
162.7 (d), 132.0 (s), 113.7 (2d), 105.2 (d), 53.74 (t). 19F
NMR (376 MHz, D2O) δ ppm −109.33-(-109.46) (m, 2F,
CF). HRMS (ESI) m/z calcd for C7H8F2NO: 160.0568 [M +
H]+; found, 160.0568.
N-(4-Methoxy-2-methylbenzyl)hydroxylamine (17). 4-Me-
thoxy-2-methylbenzaldehyde (1 g, 6.7 mmol) was dissolved in
a solution of 5.0 M LPDE. Then, O-(trimethylsilyl)-
hydroxylamine (10 mmol), trimethylsilyl chloride (10
mmol), and borane/TEA complex (10 mmol) were added as
described in the general procedure. Following purification via
flash column chromatography, the product was obtained in a
32.8% yield. 1H NMR (400 MHz, CDCl3) δ ppm 7.18 (d, J =
8.2 Hz, 1H, ArH), 6.73 (d, J = 2.7 Hz, 1H, ArH), 6.70 (dd, J =
8.2, 2.7 Hz, 1H, ArH), 4.00 (s, 2H, CH2), 3.78 (s, 3H, CH3),
2.35 (s, 3H, CH3).
13C NMR (101 MHz, CDCl3) δ ppm 158.9
(s), 138.4 (s), 131.3 (d), 126.6 (s), 115.8 (d), 110.8 (d), 54.9
(q), 54.9 (t), 19.1 (q). HRMS (ESI) m/z calcd for C9H14NO2:
168.1025 [M + H]+; found, 168.1027.
N-(2,6-Dimethoxybenzyl)hydroxylamine (19). 2,6-Dime-
thoxybenzaldehyde (1 g, 6 mmol) was dissolved in a solution
of 5.0 M LPDE. Then, O-(trimethylsilyl)hydroxylamine (9
mmol), trimethylsilyl chloride (9 mmol), and borane/TEA
complex (9 mmol) were added as described in the general
procedure. Following purification via flash column chromatog-
raphy, the product was obtained in a 29.8% yield. 1H NMR
(400 MHz, CDCl3) δ ppm 7.19 (t, J = 8.4 Hz, 1H, ArH), 6.54
(d, J = 8.4 Hz, 2H, ArH), 3.93 (s, 2H, CH2), 3.81 (s, 6H,
CH3).
13C NMR (101 MHz, CDCl3) δ ppm 159.4 (2s), 128.6
(d), 114.4 (s), 103.9 (2d), 55.8 (2q), 47.9 (t). HRMS (ESI)
m/z calcd for C9H13NO3: 184.0968 [M + H]
+; found,
184.0964.
Log P Calculations. The compounds were equilibrated in
a two-phase octanol−water system in small vials, and high-
performance liquid chromatography (HPLC) was used to
determine the concentration of the compounds in each phase.
Compound concentrations (ci) were calculated using the
expression ci = k Ii, where Ii is the integral under the peak of
the HPLC chromatogram and the proportionality constant k is
called the response factor. The ratio of the integrals for the
octanol and water phase gave the partition coefficient (P):
P ci ci k Ii k Ii
Ii Ii




Bacterial Strains and Growth Conditions. Wild-type P.
aeruginosa ATCC 15692 (CECT 4122), Staph. aureus ATCC
12600 (CECT 86), Staph. epidermidis ATCC 1798 (CECT
231), and E. faecalis ATCC 19433 (CECT 481) were obtained
from the Spanish Type Culture Collection (CECT). E. coli
O157:H7 Δstx was obtained from laboratory collection, and B.
anthracis Sterne 7700 pXO1−/pXO2− was obtained from the
Swedish Defence Research Agency. These strains were stored
at −80 °C as glycerol stocks. To obtain inocula for
examination, the strains were cultured overnight on trypticase
soy agar (TSA) (Scharlau, Spain) or Luria agar (Scharlau,
Spain) at 37 °C. Tryptic soy broth (TSB) (Sharlau, Spain) or
Luria Broth (LB) was used to culture bacteria at 37 °C.
The murine macrophage J774.A1 cell line (DSMZ ACC
170) was maintained in Dulbecco’s Modified Eagle’s medium
(DMEM) with L-glutamine (Gibco BRL, Grand Island, NY)
supplemented with 10% heat-inactivated fetal bovine serum
(FBS, Lonza Ltd., Switzerland), containing 100 U/mL
penicillin G (Lab ERN, Barcelona, Spain) and 100 μg/mL
streptomycin (Reig Jofre Laboratory, Barcelona, Spain)
(complete medium), at 37 °C in a humidified atmosphere
with 5% CO2.
Antibacterial Susceptibility Testing. To determine
survival of the different strains in the presence of different
potential inhibitors, each bacterial strain was grown in TSB
medium to initial exponential log phase (OD550 ≈ 0.1) and
plated in a microtiter plate with different concentrations of the
antimicrobial agents, following the Clinical Laboratory Stand-
ards Institute (CLSI) guidelines.37 Growth curves were
monitored for 8 h, taking the OD550 nm every 15 min in a
microplate reader (Infinite M200 Microplate Reader, Tecan).
Bacteria diluted in media with no compound were used as a
positive control of bacterial growth.
The minimal inhibitory concentration 50% (MIC50) was
defined as the compound concentration that reduces bacterial
growth, determined as the OD550, by 50%.
Determination of Mammalian Cytotoxicity. Murine
macrophage cells (6 × 104 per well) were seeded onto 48 well
tissue culture plates in complete medium (Gibco) without
antibiotics, in the presence of different doses of compounds or
left untreated. After 24 h of exposure to the different
compounds, culture supernatants were removed, and cell
viability were measured by the addition of 10% (w/v) of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) in complete medium was added and incubated for 3
h at 37 °C. Then, water-insoluble dark blue formazan was
dissolved by adding acidic isopropanol. Absorbance was
measured at 550 nm using a microplate reader (Infinite
M200 Microplate Reader, Tecan). Results were expressed as
the percent absorbance of treated versus untreated control
cultures.
The 50% cytotoxicity inhibitory concentration (CC50) of
each drug was determined from dose−response curves. On the
basis of the CC50 (24 h) and MIC50 (8 h) values, the selectivity
index (SI = CC50/MIC50) was calculated.
Fluorescent Microscopy Viability Test Analysis. Over-
night cultures of B. anthracis, Staph. aureus, P. aeruginosa, and
E. coli were diluted in fresh TSB or LB medium, grown to the
beginning of exponential phase (OD550 ≈ 0.3), and different
compound concentrations were added. After 3 h of incubation
at 37 °C under shaking conditions, cells were harvested and
stained using the LIVE/DEAD BacLight Bacterial Viability Kit
(Molecular Probes) for 30 min at room temperature under
dark conditions, followed by one sterile phosphate-buffered
saline (PBS) wash to remove nonspecific stain. Fluorescent
bacteria were visualized by a Nikon inverted fluorescent
microscope ECLIPSE Ti-S/L100 (Nikon) coupled with a DS-
Qi2 Nikon camera.
Static Biofilm Formation Assay. P. aeruginosa PAO1
static biofilms were grown on microplates following the
protocol previously described.32,38 An overnight grown culture
of P. aeruginosa in TSB was diluted to an OD550 of 0.1 in sterile
TSB medium supplemented with 0.2% glucose and added to a
96 well microtiter plate with pegs (Nunc-TSP, Thermo
Scientific) (200 μL per well). After 24−48 h incubation at
37 °C in a humid chamber, the culture supernatant was
discarded, and the pegs were washed three times with sterile
PBS to remove nonadherent cells. After rinsing, the biofilms
were treated with different radical scavenger’s concentrations
using twofold serial dilutions in TSB medium supplemented
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with 0.2% glucose. After 24 h of treatment, peg lids were
transferred to a new plate and rinsed three times with PBS.
Adherent bacteria were first fixed with 98% methanol for 15
min, allowed to dry for 5 min, and then stained with crystal
violet (1%) for 10 min. An excess of crystal violet was washed
gently with water, and pegs were dried in air for 5 min. The
dye bound to the cells was dissolved with acetic acid 33%, and
absorbance was read with a microplate reader (Infinite M200
Pro Multimode Microplate Reader, Tecan) at a wavelength of
570 nm.
The static biofilm formation assay for Staph. aureus and E.
coli was assessed following the previous protocol but using flat-
bottom 96 well polystyrene plates with lid (tissue culture-
treated polystyrene, Costar 3596, Corning Inc., NY), in the
case of Staph. aureus, and 96 well PVC plates, in the case of E.
coli.36
Flow Cell Biofilm Assay. P. aeruginosa biofilm formed
under a continuous flow was cultured in a flow cell system, as
previously described32,39 with some modifications. Channel
flow cells (made of Perspex poly(methyl methacrylate)), with a
channel size of 40 × 4 × 1 mm (DTU Systems Biology,
Technical University of Denmark)), were used and covered
with a no. 1 24 × 50 mm glass coverslip (Deltalab, ref
D102450), which served as the biofilm substratum. Each flow
cell channel was inoculated with 350 μL of a P. aeruginosa
culture, diluted to an OD550 = 0.1, and left without medium
flow for 1 h. The biofilm was then allowed to grow in LB
medium supplemented with 0.04% glucose under nutrient flow
conditions (3 mL/h) for 96 h at room temperature. The flow
was then stopped, and different concentrations of compounds
and CIP diluted in the medium were injected afterward to the
formed biofilms. Medium without any added compound was
injected in a channel as a control for biofilms without
treatment. After 24 h, treated biofilms were dyed with 6 μM
SYTO 9 and 30 μM propidium iodide (LIVE/DEAD BacLight
Bacterial Viability Kit (Molecular Probes)) for 30 min under
dark conditions and afterward washed with PBS. Biofilms were
imaged with CLSM (Leica TCS-SP5, Leica Microsystems,
Heidelberg, Germany) using excitation and emission wave-
lengths of 488 and 514 nm, respectively. Sections (250 × 250
μm) were scanned at a 40× magnification, and Z-stacks were
obtained with a z-step size of 0.388 μm. The acquired images
were analyzed using ImageJ software (National Institute of
Health, USA) and Comstat2 software,40 which were used to
quantify biofilm biomass and thickness.
Radical Scavenging Activity Determination. The
capacity of the N-HA compounds to scavenge free radicals
was evaluated by determining the in vitro scavenging of the
stable free radical DPPH· (Sigma-Aldrich), which has an
absorption peak at 517 nm in its radical form. Twofold
dilutions of the different compounds were prepared in
methanol in a 96 well microplate with final concentrations
ranging from 256 to 0.5 μM, and DPPH· dissolved in methanol
was added to initiate the reaction with a final concentration of
70 μM. The microplate was incubated at 30 °C under dark
conditions, and the absorbance was read at 517 nm after 8 and
12 h of incubation using a microplate reader (Infinite M200
Microplate Reader, Tecan). AA and HU were used as reference
radical scavengers. The percentage of radical inhibition was
calculated using the absorbance value of 70 μM DPPH·
without any compound as a reference, and the IC50 value for
each compound was calculated from the linear interval of the
curve.
Analysis of NrdA Expression Using Western Immuno-
blot. P. aeruginosa PAO1 NrdA expression was determined in
protein extracts from cultures in the presence or absence of N-
HA compounds or HU. To do so, Western blot was
performed, as previously described.20 SDS−PAGE with
normalized protein extracts was run, transfer was carried out
in a PVDF membrane, and blotting was done using anti-NrdA
rabbit polyclonal antibody (Agrisera, Sweden) at a 1/750
dilution and Goat Anti-Rabbit IgG HRP Conjugate (Bio-Rad)
as a secondary antibody at a 1/500 dilution. Amersham ECL
Prime Western Blotting Detection Reagent (GE Healthcare)
was used for chemiluminescence detection and visualized using
the LAS4000 mini system (GE Healthcare).
DPA Assay for dNTP Quantification. dNTP levels in P.
aeruginosa PAO1 cultures were determined following the DPA
assay for purine dNTP estimation, as previously described.28,29
Bacterial pellets from PAO1 cultured in the presence or
absence of N-HA compounds or HU were suspended in a lysis
buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM DTT,
5% glycerol), sonicated in an ultrasonic processor (Branson
Sonifier SFX550) until clear, and centrifuged at 20,000g for 30
min. Pellet was discarded, and the protein concentration of
bacterial extracts was quantified using Bradford assay (Bio-
Rad). Protein concentration was then adjusted for all the
samples, and 0.1 mL of each extract was mixed with 0.4 mL of
0.5 M chloroacetamide in 0.25 M potassium phosphate buffer
(pH 7.3). The mixture was incubated for 10 min at 90 °C and
cooled to room temperature, and 2 mL of DPA reagent (2 g of
DPA dissolved in 100 mL of acetic acid and 2.75 mL of sulfuric
acid) was added and incubated at 38 °C for 4 h. Absorbance
values at a wavelength of 595 nm were used to determine
relative dNTP levels.
Statistical Analysis. All data were statistically analyzed
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